Article

Eyeonics clarifies lens will treat presbyopia

Aliso Viejo, CA-Eyeonics Inc. is altering the wording of the physician's labeling on its Crystalens IOL to indicate better that it can treat presbyopia.

Aliso Viejo, CA-Eyeonics Inc. is altering the wording of the physician's labeling on its Crystalens IOL to indicate better that it can treat presbyopia.

The wording previously did not specify that patients with presbyopia would benefit, but a number of clinical Web sites have included that in their explanations of the lens and refractive lensectomy.

The new label indicates that the Crystalens is intended for primary implantation in the capsular bag for the correction of aphakia "secondary to the removal of a cataractous lens in adult patients with and without presbyopia."

"Prospective patients will realize that they are going to receive a new technologically advanced lens that replaces their dysfunctional natural lens as well as providing them a viable option to restore their continuous range of vision that they enjoyed earlier in life," he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.